Fact CheckerSign in

NCT06997042Recruiting

Creation of Arteriovenous Fistulas for Hemodialysis Using the End-to-side Anastomotic Technique vs. Piggyback.

Creation of Arteriovenous Fistulas for Hemodialysis Using the End-to-side Anastomotic Technique vs. Piggyback. Randomized Clinical Trial

Source: ClinicalTrials.gov · Last updated 18 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

This study is designed to compare two surgical techniques used to create arteriovenous fistulas (AVFs), which are necessary for hemodialysis in patients with advanced chronic kidney disease (CKD). AVFs are preferred over other forms of vascular access because they last longer and have fewer complications. However, many AVFs fail to mature properly, making them unusable for dialysis. The two techniques being studied are the traditional End-to-Side (ETS) method and a newer technique called Piggyback Straight Line Onlay Technique (pSLOT). Early studies suggest that pSLOT may reduce complications like narrowing (stenosis), clotting (thrombosis), and failure of the AVF, but more robust data from randomized clinical trials is needed. Patients aged 18 or older with stage 4 or 5 CKD, who are eligible for a new AVF and meet health criteria, may participate. During the operation, participants are randomly assigned to receive either the ETS or pSLOT technique. The procedure is done under local or regional anesthesia. Follow-up appointments are scheduled at 1 and 12 months to assess fistula maturation, blood flow, and whether it can be successfully used for dialysis. Remote follow-ups are allowed if needed. Participation is voluntary, requires informed consent, and all data is kept strictly confidential. The study follows national and international ethical standards and has been approved by an ethics committee.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
130 (estimated)
First submitted
21 May 2025
Start date
1 May 2025
Primary completion date
1 Oct 2027
Lead sponsor
Hospital Clinic of Barcelona
NCT number
NCT06997042

What you commit to

  • Study type: Interventional
  • Planned participants: 130
  • From 1 May 2025 to the primary completion date, 1 Oct 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Arteriovenous prostheses (non-native fistulas), previous arteriovenous fistula repairs, arteriovenous accesses created in the lower extremities, and unusual (exotic) accesses.
  • Repair of previous arteriovenous accesses (proximal reanastomoses).

Other illness

  • Any other condition that, in the investigator's judgment, prevents an adequate evaluation of the safety and efficacy of the study or poor compliance.

Lab values

  • History or evidence of serious systemic illness, including:
    • Cardiac disease (New York Heart Association functional class III or IV, as evidenced by the inability to lie still), myocardial infarction within 6 weeks prior to randomization, ventricular tachyarrhythmia requiring ongoing treatment, or unstable angina.
    • Suspected or documented hypercoagulable or hypocoagulable state or Clinically significant active infection (White blood count \> 15,000 cells/mm3) other than the use of a treated CVC.

Other

  • Pregnant women.
  • Life expectancy \<1 year.
  • Known or suspected central venous stenosis/occlusion on the side of the planned access.
  • Biological immunosuppression.
  • Patient unwilling or unable to attend follow-up follow-ups.

Who the study is looking for

  • Age \> 18 years
  • Able to meet protocol requirements, including follow-up.
  • Incident or prevalent patient with advanced chronic kidney disease in the hemodialysis stage (stage 5D).
  • In predialysis patients (stage 5), if renal replacement therapy (hemodialysis) is anticipated to be required within the next 6 months (based on standard clinical criteria).
  • Who, based on their associated pathology and according to medical criteria, can withstand the initial surgery and arteriovenous access maintenance procedures.
  • Have a current ultrasound with preoperative venous and arterial mapping.
  • Meet the anatomical requirements for AVF creation:
    • Wrist: artery \>2 mm, vein \>2 mm in diameter
    • Elbow: artery \>3 mm, vein \>3 mm in diameter
    • Absence of arterial calcification or occlusion, or other aberrant arterial anatomy.
    • Adequate arterial and venous patency.
    • Vein-to-skin distance \<5 mm.
  • Candidate for creation of a native arteriovenous fistula for hemodialysis, either distal (radiocephalic) or proximal (humerocephalic or humerobasilic).
  • No immediate transplant scheduled within the next 60 days (inclusion on the kidney transplant waiting list is not a contraindication for entry into the study, nor for the creation of an arteriovenous fistula).
  • No prior arteriovenous surgeries in the same or proximal location.
  • Correct understanding of the study conditions and acceptance to participate.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Hospital Clinic de Barcelona
Coordinator of this site? Confirm its status
BarcelonaSpainRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.